培门冬酶治疗结外NK/T细胞淋巴瘤的近期疗效及安全性  

Safety and efficacy of oncaspar in the treatment of extranodal NK/T cell lymphoma

作　　者：田颖[1] 陈淑霞[1] 胡青竹[1] 

机构地区：[1]河南省商丘市第一人民医院血液科,476100

出　　处：《中国实用医刊》2016年第24期35-37,共3页Chinese Journal of Practical Medicine

摘　　要：目的：探讨培门冬酶治疗结外 NK/ T 细胞淋巴瘤患者的近期疗效及安全性。方法随机选取2013年10月至2015年10月结外 NK/ T 细胞淋巴瘤患者（鼻型）60例，根据数据表法分为治疗组与对照组，每组30例，治疗组给予培门冬酶联合 GLD[吉西他滨（Gem）、奥沙利铂（L-OHP）、地塞米松（DXM）]方案治疗，对照组给予左旋门冬酰胺酶（L-ASP）联合 GLD 方案治疗，观察并对比两组患者的治疗效果及不良反应。结果治疗组完全缓解率、总有效率分别为43.33％、90.00％，显著高于对照组（16.67％、66.67％），差异有统计学意义（P ＜0.05）；治疗组Ⅲ～Ⅳ度肠胃道反应、粒细胞计数下降、中枢神经系统毒性、过敏反应发生率分别为16.67％、6.67％、10.00％、6.67％，均显著低于对照组（40.00％、26.67％、33.33％、43.33％），差异有统计学意义（P ＜0.05）。结论对结外NK/ T 细胞淋巴瘤患者采用培门冬酶治疗，能有效改善患者的临床症状及体征，近期疗效显著，且不良反应发生率更低，程度更轻，更利于患者耐受，值得推广。Objective To investigate the efficacy and safety of oncaspar in the treatment of ex-tranodal NK/ T cell lymphoma. Methods From October 2012 to October 2014,60 patients with ex-tranodal NK/ T cell（nasal type）were selected,and divided into treatment group and control group,with 30 cases in each group. The patients in treatment group were given oncaspar combined with GLD program [gemcitabine（Gem）,oxaliplatin（L-OHP）,dexamethasone（DXM）],and the patients in control group received L-asparaginase（L-ASP）combined with GLD program. The treatment effects and the main ad-verse reactions of the two groups were observed and compared. Results The complete remission rate and total effective rate in treatment group were 43. 33% ,90. 00% ,respectively,were significantly high-er than those in control group（16. 67% ,66. 67% ）,the differences were significant（P 〈 0. 05）. In the treatment group,the incidence of Ⅲ-Ⅳ degree gastrointestinal tract,decreased neutrophil count,central nervous system toxicity,allergic reactions were 16. 67% ,6. 67% ,10. 00% and 6. 67% ,which were significantly lower than those in control group（40. 00% ,26. 67% ,33. 33% ,43. 33% ）,the differences were significant（P 〈 0. 05）. Conclusions Oncaspar in treatment of extranodal NK/ T-cell lymphoma patients,can effectively improve the clinical symptoms and signs. The recent curative effect is obvious, and the incidence of adverse reaction is lower,the degree is lighter,and is more conducive to the pa-tient’s tolerance,so it is worthy of promotion.

关 键 词：鼻型结外NK/T细胞淋巴瘤 培门冬酶 左旋门冬酰胺酶 GLD方案 

分 类 号：R733.1[医药卫生—肿瘤]